Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow
26 8월 2024 - 9:00PM
Scorpius Holdings, Inc (NYSE
American: SCPX) (“Scorpius” or “the
Company”), an integrated contract development and manufacturing
organization ("CDMO"), today released a letter to shareholders from
its CEO Jeff Wolf:
"We are excited to share an update on Scorpius
as we continue to position the company to take a lead role in
catering to the rapidly growing biologic and cell therapy markets.
Over the past several years, we have made significant investments
designed to establish Scorpius as a leading biologic manufacturing
CDMO. Notably, we have expanded our mammalian and microbial
production capability to enable us to offer a broad range of
biologic manufacturing services to our customers. Our robust
investments and ongoing efforts have already resulted in a
threefold increase in revenue for the first half of 2024. Our
current sales pipeline now includes more than $100 million in
weighted opportunities across the biopharmaceutical and government
sectors.
Given the extensive opportunities before us, we
recently completed a financing, raising approximately $14.4 million
in gross proceeds. These funds will enable us to better service our
existing clients as well as attract larger prospective customers as
we diversify our customer base with a strong mix of commercial and
government opportunities. Additionally, we have started
transitioning several key clients from the process development
phase into full-scale manufacturing, enabling an additional revenue
stream and marking a significant shift in our operational
focus.
We believe that Scorpius is now exceptionally
well-positioned to service new and existing clients, expand its
service offering and achieve positive cash flow in the near future.
Given these overarching goals, we are taking steps to align senior
executive compensation with our growth objectives, contingent on
meeting sales targets and booking goals.
We’ve built and staffed a state-of-the-art CDMO
with a scalable and high-margin business model. Scorpius’ profile
and reputation for quality biomanufacturing is indeed growing in
the industry. With the closing of this financing, we are now well
positioned to deliver significant returns to our shareholders in
the years to come."
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated
contract development and manufacturing organization (CDMO) focused
on rapidly advancing biologic and cell therapy programs to the
clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions, and include
statements such as continuing to position the Company to take a
lead role in catering to the rapidly growing biologic and cell
therapy markets, the current sales pipeline now including more than
$100 million in weighted opportunities across the biopharmaceutical
and government sectors, the funds raised enabling the Company to
better service its existing clients as well as attract larger
prospective customers the Company being well-positioned to service
new and existing clients, expand its service offering and achieve
positive cash flow in the near future and being well positioned to
deliver significant returns to the Company’s shareholders in the
years to come. Important factors that could cause actual results to
differ materially from current expectations include, among others,
the Company’s ability to expand its large molecule biomanufacturing
CDMO services, attract new customers, profit from its pipeline and
continue to grow revenue; the ability to capture a meaningful
market share; the ability to generate meaningful cash flow and
become cash flow positive; the Company’s financing needs, its cash
balance being sufficient to sustain operations and its ability to
raise capital when needed, the Company’s ability to leverage fixed
costs and achieve long-term profitability; the Company’s ability to
obtain regulatory approvals or to comply with ongoing regulatory
requirements, regulatory limitations relating to the Company’s
ability to successfully promote its services and compete as a pure-
play CDMO, and other factors described in the Company’s annual
report on Form 10-K for the year ended December 31, 2023,
subsequent quarterly reports on Form 10-Qs and any other filings
the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017ir@scorpiusbiologics.com
Scorpius (AMEX:SCPX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Scorpius (AMEX:SCPX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024